Slowed relaxation in diabetic cardiomyopathy (CM) is partially related to diminished expression of the sarcoplasmic reticulum (SR) Ca 2+ -ATPase SERCA2a. To evaluate the impact of SERCA2a overexpression on SR Ca 2+ handling in diabetic CM, we 1) generated transgenic rats harboring a human cytomegalovirus enhancer/chicken β-actin promotor-controlled rat SERCA2 transgene (SERCA2-TGR), 2) characterized their SR phenotype, and 3) examined whether transgene expression may rescue SR Ca 2+ transport in streptozotocin-induced diabetes. The transgene was expressed in all heart chambers. Compared to wild-type (WT) rats, a heterozygous line exhibited increased SERCA2 mRNA (1.5-fold), SERCA2 protein (+26%) and SR Ca 2+ uptake (+37%). Phospholamban expression was not altered. In SERCA2-TGR, contraction amplitude (+48%) and rates of contraction (+34%) and relaxation (+35%) of isolated papillary muscles (PM) were increased (P<0.05 vs. WT, respectively); the lusitropic and inotropic responses of PM to forskolin were stronger than in WT. In diabetic myocardium with SR dysfunction, Ca 2+ uptake and SERCA2 protein of SERCA2-TGR were 1.3-fold higher (P<0.05 vs. diabetic WT). Thus, a SERCA2 overexpression in rat heart improves Ca 2+ uptake, accelerates relaxation and compensates, in part, for depressed Ca 2+ uptake in diabetic CM. Therefore, SERCA2 expression might constitute an important therapeutic target to rescue cardiac SR Ca 2+ handling in diabetes.
diabetes (3) (4) (5) (6) . Altered cardiac relaxation in diabetic rat models is associated with abnormal cellular Ca 2+ handling (7-9) due to impairment of Ca 2+ transport processes in the sarcolemma (10-12) and the sarcoplasmic reticulum (SR) (4, 5, 13, 14) . In particular, the removal of cytosolic Ca 2+ into the lumen of the SR--the major contributing process for cardiac relaxation, which is catalyzed by the Ca 2+ ATPase SERCA2a--is defective in the diabetic cardiomyocyte (4, 5, 13) . The underlying mechanism for this defect remains, however, poorly understood. Candidate mechanisms may involve impaired regulation of the Ca 2+ pump by reversible phospholamban (PLB) phosphorylation (14), alteration of the membrane lipid environment (4, 15) , damage by free radicals (16), unrecognized proteolysis (17), or covalent modification of the Ca 2+ ATPase (18), defective energy supply of the Ca 2+ pump (19), and decrease in SR Ca 2+ ATPase expression and abundance (14, (20) (21) (22) 24) . With respect to the latter, controversial results have been reported. Thus, Zarain-Herzberg et al. (23) could not find significant reduction of SERCA2 mRNA and protein levels in the diabetic rat heart. Evidence has also been provided that the diminished expression of cardiac SR proteins in the diabetic myocardium can be restored by correcting the metabolic disorder by using insulin therapy (14, 22) . Whether other interventions directed specifically at SR protein expression without influencing the metabolic status of diabetic animals can be used to improve SR Ca 2+ handling in the diabetic heart has not been proved. So far, various therapeutic approaches such as adenoviral transfection, gene-knockout, and transgenic techniques for specifically targeting the SR Ca
2+
ATPase (25-28) or its activity modulator, PLB (29, 30), have been applied to rescue SR Ca 2+ handling and myocardial contractile function in diseased states other than diabetic cardiopathy. In this context, we hypothesize that defective SR Ca 2+ transport function in the myocardium of diabetic rats can be compensated for by increasing the abundance of Ca 2+ ATPase molecules, using a transgenic approach. To examine this hypothesis, we first generated and characterized transgenic rats overexpressing the cardiac SR Ca 2+ ATPase SERCA2a (SERCA2-TGR) and then analyzed the SR Ca 2+ transport function and Ca 2+ ATPase abundance 6 wk after these transgenic animals were made diabetic by a single injection of STZ.
MATERIALS AND METHODS
The investigation conforms with institutional guidelines for care and use of laboratory animals and the German Animal Protection Law. Transgenic rats were generated and partially bread at the Max Delbrück Center for Molecular Medicine (Berlin, Germany).
Construction of transgenic rats
We established transgenic rat lines carrying in addition to the endogeneous SERCA2 gene the rat SERCA2a cDNA under the control of a human cytomegalovirus immediate early enhancer (hCMVenhancer) linked to the chicken β-actin (cβA) promotor, first cβA exon, first cβA intron, and part of the second cβA exon. This construct has been described and used previously by us for the generation of SERCA2 transgenic mice (31). The 6.3-kb SERCA2 expression unit was used for pronuclear microinjection into fertilized oocytes from Sprague-Dawley rats to produce transgenic rats according to Mullins and Ganten (32) . Genomic DNA (20 µg) isolated from tail biopsies of 3-wk-old rats was digested with Apa I endonuclease and subjected to Southern blot analysis according to a standard procedure. Digested genomic tail DNA was then resolved on a 1% agarose gel, transferred to a nylon membrane by vacublotting, and hybridized to a Apa I-Apa I [
32 P]-labeled transgene-specific probe of ∼0.9 kb. The probe corresponded to the first cβA intron. In SERCA2 transgene positive rats, this probe would specifically hybridize to a 1.2-kb fragment that is generated by Apa I digestion of genomic tail DNA.
Diabetic animal model
Overnight fasted male wild-type (WT) and SERCA2 transgenic rats weighing ~300 g were injected i.p. with either STZ (65 mg/kg body weight) or the buffered vehicle (0.1 mol/l citrate, pH 4.5) as described previously (33). In STZ-treated rats, the presence of hyperglycemia was confirmed by glucose estimation in blood samples obtained from the tail vein. Maximum hyperglycemic blood glucose of >24 mMol/l were reached 14 days after STZ injection. Animals were sacrificed at 6 wk after induction of diabetes. Heart samples were immediately frozen in liquid nitrogen and stored at -80°C until use for biochemical analysis.
Determination of left ventricular function
Each rat was anesthetized with an i.p. injection of 35 mg/kg ketamin and 65 mg/kg thiobutabarbital sodium. The right carotid artery was isolated and cannulated with a solid-state pressure transducer catheter (Micro-Tip 3F, Millar Instruments), which was connected to a personal computer (TSE Biosystems GmbH). The catheter was advanced into the left ventricle for measurement of pulsative LV pressure changes. As indices of global contractility and relaxation, the LV systolic pressure (LVP) as well as the maximum rates of pressure rise (dP/dt max ) and fall (dP/dt min ) were determined, respectively.
Isolation of RNA and Northern blot analysis
Total cellular RNA was isolated from atrial, right, and LV myocardium as well as from other tissues by using TRIzol Reagent (GIBCO-BRL, Life Technology). RNA samples were stored at -80°C in diethyl pyrocarbonate-treated water. The integrity of the RNA was checked by agarose gel electrophoresis, using ethidium bromide staining. RNA concentration was evaluated in triplicate at 260 nm. Levels of SERCA2 mRNA were detected by Northern blot analysis, using previously described protocols for electrophoresis, capillary transfer, and hybridization (34). To characterize the SERCA2 transgene expression, a 1.6-kb EcoR I-EcoR I restriction fragment corresponding to the 5'-end of the rat SERCA2 cDNA was used. For normalization purposes, blots were also hybridized with a 1.2-kb Pst I-Pst I chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) fragment and 600-bp polymer chain reaction (PCR) probe for 18S rRNA as descibed previously (34). The cDNA fragments were labeled with [α-32 P]dCTP by using a Multiprime DNA labeling kit (Stratagene, La Jolla, CA). The radioactivity associated with the individual mRNA bands was quantified using a Bio-Imaging analyzer (Model BAS 2000, Fuji, Japan).
Preparation of cardiac homogenates
Hearts or other tissues were quickly excised and immediately immersed in an ice-cold solution containing 130 mMol/l NaCl, 30 mMol/l KCl, and 10 mMol/l histidine (pH 7.4). Tissue samples were blotted and shock-frozen in liquid nitrogen. Frozen tissue was stored at -80°C. Tissue homogenates were prepared at 4°C in an ice-cold phosphoprotein protection buffer containing 50 mMol/l KH 2 PO 4 , 15 mMol/l NaF, and 1 mMol/l EDTA 250 mMol/l sucrose, 0.1 mMol/l phenylmethylsulfonylfluoride (PMSF), and 10 mMol/l histidine (pH 7.4) as reported previously (34).
Western blot analysis
Homogenate proteins were separated by electrophoresis either according to Laemmli protocol (34) in sodium dodecyl sulfate (SDS)-polyacrylamide mini gels (T=7.6%, C=2.67%) or according to Swank and Munkres (35) in maxi gels (T=17.6%, C=3.2%). Protein transfer to PVDF membranes (Roche, Mannheim, Germany), membrane blocking, as well as detection and quantification of SERCA2 and PLB with specific antibodies were performed as described previously (34). In some experiments, distinct amounts of protein per lane were used to check the linearity of the reaction.
Calcium transport measurements
Initial rates of SR oxalate-supported Ca 2+ uptake were estimated in ventricular homogenates at 37°C by a previously described standard procedure (34). The reaction medium of 0.25 mL contained 40 mMol/l imidazole (pH 7.0), 100 mMol/l KCl, 5 mMol/l MgCl2, 5 mMol/l Tris-ATP, 6 mMol/l phosphocreatine, 10 mMol/l K-oxalate, 0.2 mMol/l EGTA, 10 mMol/l NaN 3 , 0.025-0.25 mMol/l 45 CaCl 2 (1.9×10
11 Bq/mol), and 2 µMol/l synthetic protein kinase A inhibitor peptide [PKI(6-22)amide], and 10-20 µg of homogenate or membrane protein per 0.25 ml. The measurement was started by addition of homogenate. At certain time intervals, samples were filtered through 0.45-µm Millipore filters, using a vacuum pump. Washing of filters and determination of radioactivity were carried out as previously described (34).
Contractile measurements, using isolated papillary muscle preparations
Papillary muscle preparation, superfusion, measurements of contractile parameters, and analysis of data were performed as described previously (36). In brief, posterior LV papillary muscles were superfused at 31°C with a 100% O 2 -saturated solution containing (in mMol/l): NaCl 140.0, KCl 5.0, CaCl 2 1.5, MgCl 2 1.1, Tris/HCl 10.0, glucose 11.1 (pH 7.4). Muscles were stimulated by biphasic rectangular impulses of 7 ms duration at 0.5 Hz. Current was adjusted to 30% above threshold. Preload was adjusted to 30-50% of that load, which resulted in maximum developed peak force. To study the inotropic and lusitropic responses, measurements were also performed in the presence of 0.1-50 µMol/l forskolin or 1-100 nMol/l isoprenaline and after a test stimulus for 180-1000 ms following a steady-state contraction. Developed peak force (PF), the time to peak force (TPF), and the relaxation time for decline of force by 50% (RT 50 ) were determined from the force signal. Maximum rates of force development (dF/dt max ) and decline (dF/dt min ) were obtained from the dF/dt signal. In addition, maximum rate values normalized to the developed peak force value (dF/dt max /PF and dF/dt min /PF, respectively) were calculated. Plotting of developed force (F) values vs. respective (dF/dt)/F values resulted in a partly hyperbolic force-velocity relationship. Extrapolation of the hyperbolic segment to F = 0 provided a V max -equivalent, which has been previously used by us as a measure of the rate of sarcomeric shortening (36).
Miscellaneous
Protein was determined according to Lowry's method, using ovalbumin as standard after incubating samples in 1 Mol/l NaOH for 30 min. 45 CaCl 2 was obtained from Amersham Buchler GmbH & Co. KG (Braunschweig, Germany), Supra pure potassium chloride and calcium chloride from Merck (Darmstadt, Germany), and other biochemicals from Sigma-Aldrich GmbH (Deisenhofen, Germany).
Statistical analysis
Statistical comparisons between experimental groups were performed by one-way ANOVA. Bonferroni's multiple comparison test was used for analysis of group-to-group differences. Correlations were tested by regression analysis using the least-squares method. Values are means ±SE if not otherwise indicated. Statistical significance was assumed at P < 0.05.
RESULTS

Characteristics of transgenic rats
Southern blot analysis of rat genomic tail DNA with a transgene-specific probe identified four separate female and one male founder rats. One female founder was sterile, and the others passed on the transgene to their offspring. Out of these, two lines exhibited either marked growth retardation or small litter size and were therefore not used for further breeding. One of the lines, L1167, with an average litter size of 10 pups was characterized in further detail. Another line, L1375, was bred to homozygousity but became sterile in this state. A representative Southern blot of offspring of lines L1167 and L1375 is shown in Figure 1 .
Heart and body weight characteristics of heterozygous transgenic rats of line L1167 are given in Table 1 . There were no differences in weight parameters between age-and sex-matched transgenic rats and WT controls. This finding was also supported by histologic inspection of the myocardium, which indicated no obvious morphologic differences between transgenic and WT heart muscle (data not shown). The morphometrically determined cardiomyocyte diameter amounted to 11.9 ± 1.1 µm in transgenic rats and 11.6 ± 0.6 µm in WT controls.
Northern blot analysis revealed that the SERCA2 mRNA signals were markedly stronger in transgenic compared with WT rats (Fig. 2A) . Increased steady-state SERCA2 mRNA levels were found in all chambers of the heart of transgenic animals. Quantitation of the normalized LV mRNA coding for SERCA2 indicated a 1.5 ± 0.18-fold (P<0.05) increase in heterozygous SERCA2-TGR of line 1167 (Fig. 2B) . Increased SERCA2 message was also observed in other muscle tissues such as skeletal muscle, diaphragm, and esophagus as well as in kidney ( Fig. 2A) .
SERCA2 protein level and SR Ca uptake in vitro
To examine whether increased SERCA2 message was translated into increased cardiac SR Ca
2+
ATPase protein, Western blot analysis was performed using a SERCA2-specific antiserum. As shown in Figure 3A , 3C, and 3E for line L1167, SERCA2 protein level was increased by 26% in transgenic myocardium (P<0.05). By contrast, the level of immunoreactive PLB did not differ between transgenic animals and WT controls (Fig. 3B, 3D, 3F Figure 4A revealed an increase in the rate of Ca 2+ uptake in homozygous rats of a second transgenic line by 40% (P<0.05 vs. WT controls).
Left ventricular function and contractility of isolated papillary muscles
The data for LV pressure dynamics in anesthetized heterozygous transgenic rat line L 1167 are presented in Table 1 (lower part). There was no significant increase in systolic parameters (LVP, dP/dt max ) in SERCA2-TGR compared with WT controls. The maximum rate of relaxation as expressed by dP/dt min was found to be increased by 16% in SERCA2-TGR if compared to transgene negative controls (Table 1) . However, the increase did not reach statistical significance. To study further whether the increased expression of functional SERCA2 protein resulted in altered contractility, experiments with isolated papillary muscles were performed. As shown in Table 2 for basal conditions, isometrically contracting papillary muscles of SERCA2-TGR (line L1167) exhibited a faster relaxation, an increased rate of force development dP/dt max , and an increased peak force of isometric twitches (P<0.05 vs. WT). Time parameter of isometric twitches did not differ significantly between transgenic and control rats. To enforce the SR of cardiomyocytes to handle increased amounts of intracellular Ca 2+ during each heart cycle, the preparations were exposed to increasing concentrations of the positive inotropic agent forskolin that is known to cause a massive increase in intracellular Ca 2+ due to stimulation of Ca 2+ influx via L-type Ca 2+ channels (37). As shown in Figure 5 , forskolin caused typical positive lusitropic and inotropic responses in both experimental groups, and the drug dose dependently shortened the relaxation time parameter RT 50 in both transgenic and control muscles. However, this effect was much more expressed in preparations with transgenic SERCA2 overexpression (Fig. 5A) . A more pronounced hasting of relaxation with increasing concentrations of forskolin in SERCA2-TGR is also shown in Figure 5B . At 10 µMol/l forskolin, the relaxation index dF/dt min /PF was 1.3-fold higher in transgenic papillary muscles when compared to the respective predrug value. The respective increase of this parameter was <10% in WT controls. These stronger lusitropic responses in papillary muscles of SERCA2-TGR were also paralleled by stronger, but less pronounced, forskolin-induced inotropic effects ( Fig.  5C and 5D ). This holds true for the time-to-peak-force values and also for the values of the contractility index dF/dt max /PF.
SR Ca transport and SERCA2 protein in diabetic SERCA2 transgenic rats
Diabetic animals exhibited significantly reduced body and heart weights as well as typical signs of diabetes mellitus such as increased blood glucose, polydipsia, and polyuria (Table 3) . However, these values did not differ significantly between diabetic transgene negative and diabetic SERCA2 transgenic rats. Compared to nondiabetic WT papillary muscles, contractility and rate values of relaxation were significantly depressed in diabetic WT but not in diabetic SERCA2-TGR (Table 3 , lower part). To further examine whether functional overexpression of SERCA2 can counteract the well-documented depression of SR Ca 2+ transport function in diabetic cardiomyopathy (4, 5, 13, 14), we analyzed the homogenate SR Ca 2+ uptake and immunoreactive SERCA2 protein levels in transgenic rat hearts 6 wk after induction of diabetes mellitus by streptozotocin. In diabetic WT control rats, rate of Ca 2+ uptake measured at a submicromolar free Ca 2+ concentration of 0.34 µMol/l was decreased by 52% (Fig. 6) . Comparison of transgenic and WT rats with diabetes mellitus revealed 35% higher Ca 2+ uptake rate values in transgenic rats (P<0.05). Similar differences were also observed at saturating free Ca 2+ concentrations (Fig. 6 ) at which possible influences of PLB on the Ca 2+ affinity of SR Ca 2+ ATPases can be neglected. These alterations in SR Ca 2+ uptake were linked to equidirectional changes in SERCA2 protein level. After 6 wk of diabetes mellitus, the LV SERCA2 protein was significantly decreased by 33% in WT rats (Fig.  7A ). This decline was attenuated in diabetic SERCA-TGR. Compared with diabetic WT rats, the SERCA2 levels were 25% higher in diabetic transgenic rats. There was no significant difference in PLB abundance between the experimental groups ( Fig. 7B and 7C ). Furthermore, a linear relationship (r=0.77, P<0.001) was observed between rate values of SR Ca 2+ uptake and SERCA2 abundance if the respective values for nondiabetic and diabetic WT rats as well as for diabetic SERCA2-TGR were plotted (Fig. 8) .
To further examine whether a partial recovery of SR Ca 2+ transport function in diabetic SERCA2 overexpressors could restore defective cardiac contractile function in diabetes to normal, we analyzed the contractile responses of isolated papillary muscles to β-adrenergic stimulation as well as to extrasystolic test stimuli. As shown in Figure 9 , the positive lusitropic ( Fig. 9A and 9B ) and inotropic ( Fig. 9C and 9D ) responses to these interventions were markedly depressed in diabetic WT rats compared with nondiabetic WT controls. This depression did not occur or only partially occurred in diabetic transgenic rats overexpressing SERCA2a. In particular, hasting of relaxation with increasing concentrations of isoprenaline as indicated by the RT 50 and index of relaxation (dF/dt min /PF) values in Figure 9A and 9B was similar in diabetic SERCA2-TGR and nondiabetic WT rats but markedly reduced in papillary muscles of diabetic WT rats. This was associated with an attenuated depression of the postextrasystolic potentiation (PEP) in response to extrasystolic stimuli compared with diabetic WT rats (Fig. 9C) . As PEP is thought to reflect the Ca 2+ recycling activity of the SR in situ, the results in Figure 9C are in line with the Ca 2+ uptake data obtained in vitro, using tissue homogenates.
DISCUSSION
We have constructed a new transgenic rat model that overexpresses SERCA2 in the heart and used this model to investigate the Ca 2+ transport properties of the SR under control and diabetic conditions. Our findings indicate that 1) in SERCA2-TGR, a 26% increase in SERCA2 levels occurs due to additional expression of the SERCA2 transgene; 2) expression of the SERCA2 transgene leads to a corresponding increase in the rate of SR Ca 2+ uptake as determined by measurement of oxalate-supported Ca 2+ uptake in vitro; 3) SERCA2 transgenic rats with STZinduced diabetes mellitus showed an attenuated loss of SR Ca 2+ transport activity due to a compensatory effect of SERCA2 transgene expression; and 4) SERCA2 transgene expression in nondiabetic and diabetic SERCA2-TGR is linked to an increase in contractile activity and acceleration of relaxation as determined by analysis of isolated papillary muscle function under conditions of basal and enforced cellular Ca 2+ handling. These findings suggest that additional expression of the SERCA2 transgene can functionally substitute, in part, for loss of SERCA2 encoded by the endogenous SERCA2 gene in the diabetic rat heart. It further suggests that targeting SERCA2 expression might constitute an important therapeutic approach to rescue cardiac SR Ca 2+ handling in diabetes mellitus.
Cardiac SERCA2 expression and SR function in normal transgenic rats
In a heterozygous line of SERCA2 transgenic rats (L 1167), the steady-state LV level of SERCA2 mRNA increased 1.5-fold over the level of transgene negative rats. This increase was accompanied by a significant 26% increase in SERCA2 protein as determined by Western blotting analysis. This is in line with results that we reported previously for transgenic mice harboring the same transgene (31). The possible underlying mechanisms for the observed discrepancy between the increased SERCA2 mRNA and protein levels have not been studied in this work and remain unclear. The discrepancy might be due to inefficient translation of the SERCA2 transgene-derived mRNA, accelerated degradation of SERCA2 protein formed in excess of that derived from the endogenous SERCA2 gene, incomplete incorporation of SERCA2 molecules in to the SR membrane, or the availability of only a limited number of SR membrane insertion sites for newly formed SERCA2 molecules (31).
Functional alterations of SR function that may result from increased SERCA2 protein levels were first explored by determining oxalate-supported SR Ca 2+ uptake in LV homogenates. This method, which allows determination of the rate of ATP-driven SERCA2-catalyzed 45 Ca 2+ uptake in vitro at selected free Ca 2+ concentrations, using a Ca 2+ /EGTA buffer system, has been successfully used by us for evaluation of the Ca 2+ transporting SR function in different developmental and diseased models with altered cardiac SERCA2 protein levels (34, 38, 39). To prevent possible influences on the SR Ca 2+ pumping rate that could arise from phosphorylation of PLB by endogenous protein kinase A during the Ca 2+ uptake reaction in vitro, we included into the uptake medium 2 µMol/l of a specific protein kinase A inhibitory peptide. The SR Ca 2+ uptake was linear with time for at least 3 min in both trangenic and WT rats and was completely abolished in the presence of either 10 µMol/l Ca 2+ ionophore A23187 or 10 nMol/l of the specific SR Ca 2+ pump inhibitor thapsigargin (data not shown). This indicates specificity of uptake into SR vesicles for both transgenic and WT rats.
In preparations obtained from a heterozygous line (L1167) of transgenic rats, the rate of Ca 2+ uptake determined at different submicromolar free Ca 2+ concentrations was found to be higher than in agematched WT animals. These data suggest that expression of additional SERCA2 molecules encoded by the SERCA2 transgene are functional and do cause the increase in the SR Ca 2+ pumping activity in transgenic animals. To ensure that increased SERCA2 expression and the resultant SR Ca 2+ pumping improvement were not due to positional effects the SERCA2 transgene was integrated into the genome, we characterized the SR Ca 2+ uptake in homogenates prepared from a separate line of SERCA2 transgene rats. Homozygous animals of this separate line (L1375) exhibited a 40% higher rate of Ca 2+ uptake. By contrast, we could not detect a significant increase in SR Ca 2+ uptake in heterozygous SERCA2 rats of this line (data not shown). These findings clearly indicate that the increased SERCA2 expression and the functional SR changes are due to additional copies of the SERCA2 transgene in the genome of transgenic rats of line 1167 and 1375 above a certain threshold level. Although we have not quantified the copy number incorporated into the genome of the respective transgenic animals, these findings also appear to reflect a gene dosage effect with respect to the functional SR changes. In fact, data given in Figure 1 indicate a lower copy number in heterozygous rats of line L1375 when compared to heterozygous rats of line L1167. This could explain why functional SR changes were observed in heterozygous SERCA2 rats of line L1167 and homozygous SERCA2 transgenic rats of line L1375 but not in heterozygous animals of the latter line.
Effect of SERCA2 transgene expression on contractile function
Because the rather small increase in SERCA2a protein level in transgenic rats (Fig. 3) resulted in accelerated uptake of Ca 2+ by the SR in vitro (Fig. 4) , we determined whether this would increase the rate of relaxation in vivo. In anesthetized rats, with a 2 F micromanometer catheter in the cavity of the left ventricle, the maximum rate of relaxation as expressed by dP/dt min was found to be increased by 16% in SERCA2-TGR when compared to transgene negative controls (Table 1) . Although this finding apparently confirms results reported earlier for SERCA2 transgenic mice harboring the same SERCA2a transgene (28, 31), the increase did not reach statistical significance. This is most probably due to the large intragroup variation of the measured parameter in anesthetized animals. To avoid possible interfering influences that could arise from the anesthesia (40) or loading conditions (41), we performed further contractile measurements in isolated papillary muscle preparations under defined humoral and preload conditions. When baseline recordings for SERCA2 transgenic rats were compared with transgene negative controls, the maximum rate of relaxation was found to be significantly increased by 35% in SERCA2 transgenic rats, suggesting that the small increase in SERCA2a protein level in the myocardium of these animals is capable of significantly accelerating relaxation due to increased diastolic uptake of Ca 2+ by the SR.
In contrast to in vivo conditions, isolated papillary muscles were exposed to 31°C at a stimulation rate of 0.5 Hz. Furthermore, modulating influences of vegetative nerves and humoral factors such as epinephrine and norepinephrine are lacking. Under these conditions, the Ca 2+ cycling rates in cardiomyocytes and, hence, the amount of Ca 2+ to be handled by the Ca 2+ pumps of the SR per unit of time, are expected to be much lower than under physiological in vivo conditions. To enforce the Ca 2+ pumps of the SR to transport increased amounts of Ca 2+ across the SR membranes, we also recorded the contractile responses of papillary muscles in the presence of increasing concentrations of the adenylyl cyclase activator forskolin. This drug is known to cause a massive increase in the influx of Ca 2+ via sarcolemmal L-type Ca 2+ channels (37). The shortening of the relaxation time RT 50 in response to forskolin was significantly stronger in muscle preparations from transgenic rats compared with WT controls. This suggests that the myocardium of SERCA2-transgenic rats expressing an extra amount of SR Ca 2+ pump molecules possesses an increased lusitropic reserve compared with transgene negative controls. This is further supported by the significant differences between the values of the relaxation index dF/dt min /PF of both groups under the influence of forskolin (see Fig. 5B ).
These results may also indicate that Ca 2+ pumps encoded by the SERCA2-transgene are, at least in part, under regulatory control of PLB. Although we did not investigate the phosphorylation status of PLB in this study, one can anticipate that the inhibitory influences of nonphosphorylated PLB (42) existing in the noninnervated muscle strips under baseline conditions are progressively removed by protein kinase A-catalyzed phosphorylation of this protein with increasing concentrations of forskolin. The significant acceleration in the upstroke of the contraction force and the increase in the developed peak force under baseline conditions in the transgenic compared with nontransgenic rats as well as the differences in the forskolin-induced changes in the time-to-peak-force and the contractility index dF/dt max /PF may reflect an increase in the Ca 2+ load of the SR in transgenic rats. In fact, it is well known that an enhanced uptake of Ca 2+ into the SR will result in higher amounts of Ca 2+ available for release into the cytosol and this will result in an increased amount of activator Ca 2+ at the contractile apparatus (7, 43, 44). In fact, this has been demonstrated in isolated cardiomyocytes from SERCA2a transgenic mice (44). In general, our findings obtained in the new SERCA2 transgenic rat model are in accordance with results reported earlier for transgenic mice with cardiac overexpression of specific SERCA isoforms (31, 45-47) and provide further support for the notion that the SERCA2 transgene expression is capable of increasing the Ca 2+ pumping activity and reserve as well as the Ca 2+ load of the cardiac SR under physiological conditions.
Rescued SR Ca 2+ transport in SERCA2-TGR with STZ-induced diabetes mellitus
Slowed relaxation is a prominent feature of impaired cardiac performance in diabetic cardiopathy (3, 4, 5, 6 ). In chronic streptozotocin-induced insulin-deficient diabetes, it is mediated in part through depressed uptake of Ca 2+ by the SR cardiomyocyte (4, 5, 13). A decreased expression of the SR Ca 2+ ATPase (SERCA2a) leading to reduced abundance of Ca 2+ pumps in the SR membranes appears to be one of the contributing mechanisms (14, 20-22). In this study, we corroborate these previous findings for 6-wk-old STZ-diabetic nontransgenic rats. In fact, the insulin-deficient diabetic rat model presented in this study reveals significantly decreased cardiac SERCA2a protein levels, and this concurs with a decrease in the rate of SERCA2a-catalyzed uptake of Ca 2+ by the SR and relaxation. However, when transgenic rats overexpressing SERCA2a were made diabetic, both the SERCA2a protein level and the rate of SR Ca 2+ uptake were significantly higher than in diabetic nontransgenic rats; and this was associated with a partial restoration of cardiac relaxation to normal.
These findings support the view that reduced SERCA2a expression in chronic insulin-deficient diabetes contributes to the decline of SR Ca 2+ uptake. Furthermore, the results provide the first experimental evidence for a SERCA2 transgene-mediated improvement of the Ca 2+ transporting function of the cardiac SR in a diabetic rat model. Note that the beneficial changes of SR Ca 2+ transport in diabetic transgenic rats were observed despite the persistence of the diabetic status. This indicates that an intervention directed specifically at SERCA2a expression without influencing the overall metabolic status is useful to improve the compromised SR Ca 2+ handling and contractile function of the diabetic heart. This conclusion is in line with results of other approaches for specifically targeting the SR Ca 2+ ATPase (25, 28) or its activity modulator, PLB (29, 30), to rescue SR Ca 2+ handling and myocardial contractile function in diseased states other than diabetic cardiopathy. In contrast to the present work, these studies used genetically engineered murine models. In particular, a SERCA2 transgene-mediated functional compensation of the defective SR Ca 2+ transport and/or the impaired cardiac performance in hypothyroidism-induced heart failure (25) as well as in pressure overload hypertrophy and failure (28) has been reported recently. Note that these transgenic mice expressed the same SERCA2a transgene that was used for generation of transgenic rats in our study.
Our data also indicate that the diabetes-related alterations in SERCA2a protein level and SR Ca 2+ ATPase function could be restored only partially by SERCA2a transgene expression. A likely explanation for this phenomenon is that altered expression of the SR Ca 2+ ATPase gene is only one of the mechanisms contributing to impaired SR Ca 2+ ATPase function under conditions of chronic insulin deficiency. Other contributing mechanisms such as alteration of the membrane lipid environment, damage by free radicals, unrecognized proteolysis or covalent modification of the Ca 2+ ATPase, defective energy supply to the Ca 2+ pump, and changes in expression and phosphorylation status of PLB may not be dismissed (14, 16). Although we did not investigate all of these candidate mechanisms, the similar intergroup differences in the SR Ca 2+ uptake values obtained at submicromolar and saturating free Ca 2+ concentrations as well as the Western blot data on PLB appear to exclude the latter as a possible underlying mechanism. Whether or not diabetesrelated changes of other components of excitation-contraction coupling other than SERCA2 abundance and function might have contributed to the observed contractile differences between diabetic WT and transgenic rats has not been studied in this work and therefore needs further investigation. In particular, possible specific differences between SERCA2 overexpressors and WT rats in cardiac myosin heavy chain isoform pattern that is affected in diabetes (48) could be important in this context.
In general, we can conclude for the chronic insulin-deficient diabetic rat model that additional expression of the SERCA2 transgene can functionally substitute, in part, for loss of SERCA2 encoded by the endogenous SERCA2 gene. The results also suggest that targeting SERCA2 expression might constitute a future potential therapeutic approach to rescue cardiac SR Ca Overexpression of SERCA2b in the heart leads to an increase in sarcoplasmic reticulum calcium transport function and increased cardiac contractility. -myosin ATPase activity and changes myosin isoenzyme distribution in the diabetic rat heart. Am J Physiol 248(5 Pt 1), E602-E606 , and calcium ion concentration in the superperfusion solution was 1.5 mM. Preload was adjusted to a load at which 30% of maximum force was developed. Values are means ±SE for n=7 each. *P<0.05, significantly different from the transgene negative control group. E and F) Representative Western blots using enhanced chemiluminescence detection for cardiac SERCA2 (100-kDa signal) and monomeric low molecular weight form (PLB low ) of phospholamban (6.5-kDa signal) of two different SERCA2 transgenic (+) and two transgene negative control rats (-) are shown. See also Materials and Methods. 9 . Response of isolated papillary muscle from nondiabetic wild-type control rats, diabetic wild-type rats and diabetic SERCA2 transgenic rats (SERCA2-TGR) of line L1167 to isoprenaline and extrasystolic stimuli. Isoprenaline-induced changes of two selected relaxation parameters are shown in A and B. In addition, parameters characterizing the inotropic response of the muscles either to extrasystolic stimuli (C) or increasing isoprenaline concentrations (D) are shown. A) Time of relaxation for decline of developed force to 50% of peak force (RT 50 ). B) Maximum rate of force decline(dF/dt min ) normalized to the respective peak force (PF) value. C) Postextrasystolic potentiation of the first postextrasystolic contraction (PEC). Test stimulus was given at 180-1000 ms following a steadystate contraction. D) Maximum rate of contraction (dF/dt max ) normalized to respective developed PF value. The steady-state stimulation rate was 0. 
